The aim of the present study is to investigate in humans the mechanism by which the oral vaccine Polyvalent Mechanical Bacterial Lysate (PMBL) can rapidly mobilize specific immune response and evaluate the efficacy of its immunostimulating activity in preventing recurrent infections of the upper respiratory tract (URTIs) in a group of patients with a medical history of URTI recurrence. Patients received, by sublingual route, PBML, an immunostimulating lysate obtained by mechanical lysis of the most common bacteria responsible for upper respiratory tract infections. The treatment was administered for 10 consecutive days/month for 3 consecutive months. After the end of the treatment period the patients were followed up for an additional 3 months. The frequency of IgM memory B cells and the expression of the activation marker CD25 in peripheral blood lymphocytes were measured using the flow cytometric method before the start and at days 30 and 90 of the treatment cycle. To correlate clinical results to immunological parameters, the patients were monitored at different time-points during the treatment and at the end of follow-up period. The results showed that PMBL exerts a therapeutic and preventing effect in acute and recurrent infections of the upper respiratory tract and that this effect correlated with the activation and enhancement of both IgM memory B lymphocytes (CD24+/CD27+ cells) and IL2 receptor-expressing lymphocytes (CD25+ cells) involved either in humoral or cellular immunity.
frequent in patients with anatomical or functional asplenia (3) .
The use of oral vaccines composed by bacterial lysates may be an effective strategy to prevent or limit URTIs. Prevention by vaccination is an important issue due to the high frequency of these infections in the population, both for the significant frequency of serious consequences (hearing loss, sepsis, death) and for the increasing development of antibiotic resistance (4) (5) (6) (7) (8) (9) (10) .
PMBL (Polyvalent Mechanical Bacterial Lysate) is an oral anti-bacterial vaccine obtained by mechanical lysis of eight different strains of Gram positive and Gram negative bacteria commonly responsible for respiratory tract infections (8) (9) (11) (12) . PMBL has been proved to be effective in the prophylaxis of URTIs (8) (9) (11) (12) and has been shown to activate immune responses in vitro and in vivo by different subsets of immune competent cells, both for humoral and cellular immunity (10) (11) (13) (14) . In particular, PMBL was found to stimulate the early production of Igs (9) .
Recently a new subpopulation of B lymphocytes has been described and called "IgM memory B cells" (15) (16) . This subset generates an immunological response, "intermediate" between innate and acquired immune responses. In fact, the antibodies made by IgM memory B cells act as the emergency and early defence against all infections, since their low-affinity allows the flexible recognition of different antigens. Moreover, they are the only B-cell defence against T-independent antigens and cannot generate germinal centers and specific long-lived memory cells (17) (18) . IgM memory B cells may originate in the spleen, in extrafollicular sites and independently from T cells (18) .
In the present study we investigate the mechanism in humans by which PMBL can rapidly mobilize specific immune response thus preventing recurrent infections of the upper respiratory tract. To this aim, in a clinical trial, we evaluated the efficacy of the bacterial extract PMBL in inducing IgM memory B cells as well as the efficacy in reducing URTIs.
In addition, on the basis of previous data (13) which demonstrated that PMBL in vitro can induce the expression of IL2 receptor in both T and B cells in human peripheral blood lymphocytes, we also verified whether in vivo PMBL administration could activate different lymphocyte subsets to express the same receptor.
Overall, the results showed that the therapeutic or preventive effect of PMBL on acute and recurrent infections of the respiratory tract correlates with the activation and enhancement of immune responses by different lymphocyte subsets involved in either humoral or cellular immunity, thus confirming our previous results in vitro.
MATERIALS AND METHODS

Patients
The trial began in January 2005 and was completed in July 2005. Patients were recruited from September 2004 to December 2004. There were 10 patients (6 females and 4 males) of age ranging from 23 to 65 years (mean 49.8), who suffered from episodes of recurring URTIs over the 12 months preceding the study (Tables I and II) . Five patients suffered from chronic pharyngotonsillitis and five patients had chronic rhinosinusitis; in addition 2 subjects were smokers.
The inclusion/exclusion criteria into this study were as follows: (a) recurrent URTIs, defined as three or more episodes during the last year (Table II) , with pathology characterized by pharyngitis, rhinorrhea, otitis, tonsillitis; (b) no recognized primary or secondary immunodeficiency, diabetes, allergy; (c) time elapse~12 month from the last episode of immunostimulant therapy or vaccination; (d)~15 days from any antibiotic therapy; (e) no concomitant therapy with corticosteroids or FANS; (t) no chronic therapy for serious pathology; (g) no occurrence of cardiovascular disease; (h) no pregnancy.
Informed consent for each participant was obtained on entry. After selection criteria were completed, consecutive numbers were assigned to the ten patients. Before the beginning of the treatment each patient was physically examined and videoendoscopy measurements of the upper respiratory tract were performed. PMBL administration PMBL (Ismigen'", Zambon Italia sri, Bresso/Milan, Italy) is a polyvalent immunostimulating vaccine obtained by mechanical lysis (by sonication) of 6 x 10 9 bacteria for each of the following eight strains: S. aureus, S. pyogenes, S. viridans, S. pnemoniae (containing 10 9 bacteria of each of the following serotypes: TYl/ EQII, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24), K pneumoniae, K ozaenae, H. influenzae serotype B. M catharralis. The product is formulated in tablets containing 50 mg offreeze-dried lysate of which 7 mg is bacteria lysate and 43 mg excipients.
Clinical response was assessed at the following time points:
TO (time 0, time before the beginning of PMBL treatment);
. T I (20 days after the end of the first 10 days of treatment); T2 (90 days after the beginning of treatment). At the end of the treatment period the patients were followed up for 3 months. At the three different time points, 10 ml heparinized whole blood samples were collected from each patient and processed for analyses (see below). One patient's blood was unable to be collected and the subject was excluded from subsequent analysis (drop out at time TO)
PBMC separation
Peripheral blood mononuclear cells (PBMC) from the patients' buffy coat samples were separated by Ficollhypaque gradient centrifugation. The mononuclear cells from the interface were harvested, washed and adjusted to 2x10 6/ml in RPMIl640-GLUTAMAX (Gibco) culture medium supplemented with 5% heath inactivated fetal calf serum (FCS, Hy-Clone).
Determination of cell surface phenotype by two color immunofluorescence staining
Isolated PBMC were washed, resuspended in PBS containing 0.5% bovine serum albumin (BSA) and 0.01% NaN} and were aliquoted for staining at I x 10 6 cells. Then, 50 III of a FITC-conjugated mouse anti-human CD24 monoclonal antibody dilution were added (mouse anti-human CD24/FITC conjugated BD PharMingen). 50 III of PE-Iabelled anti-human CD27 (for memory phenotype) (mouse anti-human CD27/PE conjugated BD PharMingen) or anti-human CD25 (for activated cells) (mouse anti-human CD25/PE conjugated BD PharMingen) were then added and the cells were incubated for 30 min at 4°C. As negative controls, aliquots of cell suspensions were incubated with an irrelevant isotype-matched mAb conjugated to the same fluorochrome as the sample. At the end of incubation the cells were washed twice and resuspended in PBS for flow cytometry.
Flow cytometry A FACScan flow cytometer (Becton Dickinson,
Mountain View, CA, USA) equipped with a 15 mW argon ion laser and filter setting for FITC (530 nm) and PE (585 nm) was used. Signals from light scatter channels and fluorescence-detecting photomultipliers (PMT) were collected in linear and logarithmic mode, respectively. The FL I and FL2 channels were set up and compensated on a tight lymphocyte gate using tubes with a single-labelled strongly positive antibody. Dead cells were excluded by forward and side scatter gating. Ten thousand cells were recorded for each test and signals from all parameters were captured as list mode data using CellQuest software (Becton Dickinson). List mode files were analyzed for surface fluorochrome positivity by FACScan Research Software (Becton Dickinson). Irrelevant isotype-specific antibody was used as a control for non-specific binding of monoclonal antibodies. Statistical markers were set using the irrelevant isotype-matched controls as reference. Typically, 1% positive cells were allowed beyond the statistical markers in these controls.
Statistical analysis
Statistical significance was determined using Student's t-test.
RESULTS
Kinetics ofinduction of "lgM memory" B cells
IgM memory B cells are recognized by the coexpression of CD24 and CD27 surface markers (15) . CD24 is a phenotypic marker that specifically recognizes all mature B lymphocytes, whereas CD27 is expressed exclusively on memory lymphocytes. Thus, among the CD24+ population, mature B cells are CD27-, whereas circulating memory B cells are CD27+.
The present results demonstrate that, as early as 20 days after the end of the first ten-day treatment cycle (Tl), PMBL induced an increase (106% vs 5,7%) of CD24+ / CD27+ memory B cells (Fig. 1) . At the end of the third treatment cycle, after 90 days of treatment (T2), the ratio among CD24+ / CD27+ and CD24+ / CD27-cells increased to 185% (Fig. I) .
Expression oflL2Receptor (CD25)
CD25 is a surface antigen corresponding to the a chain of the IL2 receptor (lL2Ra), and is considered an activation marker (19) .
The results of the experiments show that PMBL treatment induces an increase of B lymphocytes expressing surface IL2 receptors (Fig. 2) . In fact, the immunophenotypic analysis by two-color flow cytometry showed that PMBL treatment, 20 days after the end of the first ten-day treatment cycle (T I), induced a significant increase in the percentage of C024+ B lymphocytes expressing C025 when compared to the values obtained before PMBL treatment (Fig. 2) . Similarly to the induction of IgM memory B cells, at the end of the third cycle of PMBL treatment (T2) there was a further increase of IL2R positive B cells (Fig. 2) . Moreover, the analysis of IL2R expression on the whole mononuclear population after PMBL treatment reveals that at * * * * time T2 there was already a 30% increase in the expression of IL2Ra. in PBMCs (Fig. 3 ).
URTIs
The rates of URTIs episodes over the 12 months preceding the study are reported in Table I , and the types of URTIs observed during the same period are listed in Table II . Clinical response to PMBL treatment was assessed by visiting the patients at the beginning (TO), at the end of therapy (three months after the beginning of the PMBL treatment) and after the follow-up period (three months after the interruption of treatment).
The results of the study show (Table III) that during the three months of ten days/month PMBL treatment cycle a high proportion of patients remained free from URTIs. In fact, only one patient out of nine had an URTI episode (acute pharyngitis of limited duration and with a favourable outcome). At the follow-up none had had recurrence. All nine of the patients who had started the treatment completed the cycle and no side effects were observed during either the treatment or the follow up period.
During the 12 months before PMBL treatment, a total number of 57 episodes of URTIs was observed (Table I) , whereas only one patient had a recurrence during the PMBL therapy cycle, and no recurrence was observed during the 3 month follow-up period (Table III) .
DISCUSSION
The main objective of the present study is to better define in vivo the immunological mechanisms 
Days of Treatment of immunostimulating action of PMBL. The results of the study confirm the protective effect of PMBL, as shown by the reduced incidence and duration of URTls episodes observed during both the treatment and follow up periods. The results also indicate a possible mechanism of action related to the immunostimulating activity of PMBL. In fact, the data obtained demonstrate that in vivo PMBL induces the expansion of IgM memory B cells, an early subset of B memory lymphocytes (20) . In human peripheral blood, two populations of memory B cells have been identified (15, 18) . The first is the IgM memory B cell subset that expresses surface CD24 and CD27 antigens and membrane IgM. This B cell subset is responsible for immunity against T-independent antigens, such as encapsulated bacteria and other pathogens that cause recurrent and chronic infections of the respiratory tract, and requires the spleen for its generation and/or survival (15) . The second subset consists in the class-switched memory B cells expressing immunoglobulin isotypes other than IgM (21) . Switched memory B cells, differently from the IgM memory B cell subset, are highly specific, long-living cells, generated in response to infections or vaccines in germinal centres after somatic mutation, selection and class switch (21) (22) . They can develop in the spleen, but also in other lymphoid tissues, and are responsible for the immunological memory against T-dependent antigens.
It has recently been shown (16, 24) that in humans the IgM memory B cells have functions similar to murine B-1a B cells, that are the major source of natural antibodies and rapidly produce Igs in response to T-independent antigens, like encapsulated bacteria. Mice lacking B-1a B cells have low levels of natural IgM and do not produce antibodies in response to pneumococcal polysaccharide vaccines (24) . Similarly to B-la B cells, IgM memory B cells in humans cannot be detected in splenectomized and asplenic individuals and their absence is associated with an increased frequency of pneumococcal infections and impaired response to polysaccharide vaccines (2-3, 17,25) .
Infections of the respiratory tract by encapsulated bacteria remain localized and might be asymptomatic in normal individuals. In patients lacking IgM memory B cells, these infections are more frequent, severe and often develop into invasive diseases (e.g. pulmonitis, meningitis) (18) . Indeed, recurrent and chronic infections by encapsulated bacteria are the most important symptoms of all primary B-cell immunodeficiencies, but these infections never occur in individuals with T-cell defects, confirming that the reaction against these pathogens is a primary and exclusive function ofB cells (18) .
The results of the present study also show that PMBL treatment induces an increase of the percentage of CD25 expression both in B lymphocyte subset and whole PBMCs. CD25 is a surface antigen corresponding to the a chain of the IL2 receptor (IL2Ra) considered to be an activation marker (19) .
The finding that PMBL treatment increases the percentage of activated B lymphocytes expressing surface CD25 indicates that this vaccine can modulate a major mechanism in the immune response, that is the IL2-IL2R signalling, important in the survival, growth and development of the immune response (both humoral and cellular) of the different lymphocyte subsets. These data confirm the results of our previous experiments on cultured human lymphocytes that demonstrated that PMBL in vitro treatment strongly activates IL2Ra expression on B cells already after 24 h of incubation (13) .
The statistically significant increase of IL2Ra expression in the whole mononuclear subpopulation indicates that PMBL can also activate non-B immunocompetent cells. This finding confirms our earlier in vitro results on IL2Ra expression in CD4+ and CD8+ cultured T cells after PMBL treatment (13) . This previous in vitro study also showed that the incubation with PMBL activated both CD4+ and CD8+ T lymphocytes subsets to produces different types of cytokines (i.e. IL2, IL4, ILIO and IFN-y) that can induce and regulate immune responses. Thus, present data confirm the in vitro results that suggested that PMBL treatment can activate the responses of different subsets of immune competent cells both for humoral and cellular immunity (13) .
The main objective of the present study is to better define in vivo in humans the mechanism of the immunostimulating action of PMBL. However, in spite of the low number of enrolled subjects and the lack of control groups, the clinical results obtained are in agreement with previous studies performed with PMBL and confirm its efficacy in the prevention and treatment of recurrent URTIs without side effects (8) (9) (11) (12) .
Clinical results of the study are consistent with the mechanism of action of PMBL. In fact, the drug showed to decrease the severity of exacerbations and, hence, the risk of complications as well as the risk of recurrence by helping the airways to get rid of the infecting agent more rapidly. This effect is consistent in different degrees of severity of respiratory impairment (Table II ). The fact that the protective effect of PMBL is obtained through the stimulation of non-specific immunity suggests that it can be an important complement to antibiotic therapy for protection against a large variety of microorganisms.
In conclusion, these data show that the improvement of clinical conditions observed in our patients following a 3 months cycle may be related to both the increase of memory and activated B cell subsets and to the activation of other immunocompetent cells through IL2 receptor. These results further confirm that PMBL enhances immunological responses, particularly in chronic pathology and in weakened subjects, and that it can play an important role in preventing the spreading of localized infections, such as URTIs, as well as in improving the pathology of chronic URTIs in subjects with possible immune deficit (14, 26) .
